Patient Home Monitoring (PHM) Announces October 2011 Growth Figures

Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home
cardiology healthcare services, today announced monthly growth in terms of
meters shipped during the month of October 2011. 


Monthly Growth

October 2011 Meter Shipments

PHM shipped 177 meters in October 2011, the first month of fiscal 2012. Since
PHM started announcing monthly growth figures 8 months ago, PHM has shipped an
average of 162 meters per month.


At the end of each month, PHM classifies revenue into two components:



1. Existing Patient      PHM generates a recurring monthly revenue stream   
Services.                from enrolled weekly testers.                      

2. New Patient           New patients add to the existing monthly revenue   
Enrollment.              stream                                             



Once enrolled, PHM ships a meter with an expected 5-year economic life to a
patient. With this meter investment, PHM generates monthly recurring revenue by
providing weekly monitoring services to the patient.


Understanding how many meters were shipped to newly enrolled patients each month
is relevant for analyzing growth because shipment of a meter is a prerequisite
to performing INR(1) tests eligible for reimbursement(2).


"We continue to enjoy robust demand within our niche for in-home services," said
Dr. Jaime Gerber, PHM's CEO. "We are adding patients each month, increasing our
annuity-based revenue and generating more cash inflow to finance growth each
month. The key to our continued growth is our ability to purchase meters for
patients as each meter placed directly generates an annuity cash flow from the
patient. Therefore, our primary focus now is securing debt to acquire meters at
a fast enough rate to keep up with our customer demand. While the current
capital markets are challenging, we do have a business that can support
borrowing for capital equipment. We intend to secure debt in the coming months
to finance continued growth at this rate, or faster, into the years to come. "




----------------------------------------------------------------------------
                                                                          Q1
                                             Q3 2011           Q4 2011  2012
----------------------------------------------------------------------------
                                   April   May  June  July   Aug  Sept   Oct
----------------------------------------------------------------------------
Meters Shipped                       131   158   220   138   157   158   176
----------------------------------------------------------------------------
Running Average                      131   144   169   161   160   160   162
----------------------------------------------------------------------------



About PHM

PHM is a healthcare services company focused on providing in-home testing for
patients on blood thinner medications such as Coumadin(R) or warfarin. Medicare
recently expanded reimbursement for in-home patient self testing (PST) of blood
coagulation levels. PHM has a unique value proposition to cardiology groups that
manage patients on blood thinners, focusing on systemization to enroll patients
in PST. Current enrollment compliance levels may not be predictive of future
enrollment compliance levels. This unique, systemized approach creates an
opportunity for physician groups to operate more efficiently, increasing revenue
to their clinic while providing a higher standard of care for patients.


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, changes in US healthcare laws, coverage or budgets,
dependence on few payors, possible new drug discoveries, a novel business model,
dependence on key suppliers, granting of permits and licenses in a highly
regulated business, competition, low profit market segments as well as general
economic, market and business conditions, and could differ materially from what
is currently expected.


(1) International normalized ratio ("INR") tests are used as measures of current
and future sales performance. Please refer to the "Non-GAAP Measures" section of
PHM's MDA for further discussion on these operational measure


(2) Management does not mean to suggest or imply that shipment of meters is
equivalent to revenue. Meter shipment is a prerequisite, but not a guaranty, of
revenue. Management does not propose meter shipments as a non-GAAP financial
measurement, because there is no simple reconciliation between meter shipment
and GAAP revenue